Robeco Institutional Asset Management B.V. Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Robeco Institutional Asset Management B.V. reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 775,683 shares of the company's stock after selling 51,261 shares during the period. Eli Lilly and Company comprises 1.1% of Robeco Institutional Asset Management B.V.'s investment portfolio, making the stock its 11th largest position. Robeco Institutional Asset Management B.V. owned 0.08% of Eli Lilly and Company worth $598,827,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of LLY. Verus Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $268,000. Sumitomo Life Insurance Co. grew its position in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Sumitomo Life Insurance Co. now owns 25,089 shares of the company's stock worth $19,369,000 after buying an additional 476 shares during the last quarter. R Squared Ltd bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $224,000. Foster Group Inc. grew its position in shares of Eli Lilly and Company by 2.5% in the 4th quarter. Foster Group Inc. now owns 1,595 shares of the company's stock worth $1,232,000 after buying an additional 39 shares during the last quarter. Finally, Gateway Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 41.2% in the 4th quarter. Gateway Wealth Partners LLC now owns 976 shares of the company's stock worth $753,000 after buying an additional 285 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.4 %

Shares of LLY stock traded down $11.62 during mid-day trading on Friday, hitting $811.61. The company's stock had a trading volume of 2,560,693 shares, compared to its average volume of 3,849,697. Eli Lilly and Company has a 52-week low of $637.00 and a 52-week high of $972.53. The business has a 50-day moving average price of $782.29 and a 200 day moving average price of $845.82. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market cap of $770.48 billion, a price-to-earnings ratio of 87.74, a PEG ratio of 1.71 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm's revenue for the quarter was up 20.4% compared to the same quarter last year. Research analysts predict that Eli Lilly and Company will post 12.85 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio is 56.22%.

Eli Lilly and Company announced that its Board of Directors has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

Analyst Ratings Changes

LLY has been the topic of several research reports. Wells Fargo & Company dropped their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating on the stock in a research report on Tuesday. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. StockNews.com lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Truist Financial lifted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a "buy" rating in a research report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $997.22.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.